Utilization of Bevacizumab Injections in Medicare Fee For Service in the IRIS® Registry.

Abstract

Based on over 21 million intravitreal injections performed in the past 7 years, the utilization of bevacizumab has significantly decreased across all included payers. The percentage use has been lowest in patients with Medicare Fee for Service health insurance, compared with Medicare Advantage and other insurance. This might be due in part to the small margin paid when bevacizumab is used for intravitreal injections.